CAESAREA, Israel, Jan. 17, 2018 /PRNewswire/ -- DarioHealth
Corp. (NASDAQ: DRIO), a leading global digital health company with
mobile health and big data solutions, today announced it has
launched the Lightning®-enabled version of the acclaimed Dario™
Blood Glucose Monitoring System in the Australian market. The
Lightning®-enabled device ensures that Apple consumers "Down Under"
will be able to connect the Dario smart glucose meter to the latest
iOS handsets, including the brand-new iPhone X.
By some estimates, Apple iOS has over 55% market share in
Australia, and DarioHealth expects
to increase revenues in the Australian market with this launch. In
addition, Dario blood glucose test strips can be found in major
pharmacies across Australia,
especially in New South Wales and
Victoria, where it can be found in
many of the leading pharmacies, including Priceline Pharmacy, Amcal
Chemist, and Terry White Chemists.
Erez Raphael, Chairman and CEO of
DarioHealth, commented: "We are happy to confirm that we are
recommitting ourselves to the Australian market. Over the past few
months, we have been working tirelessly to get the TGA (Therapeutic
Goods Administration) Mark so we can cater to the Australian market
and help people with diabetes to manage their disease with the most
up-to-date technology Dario has to offer. We look forward to
continuing our mission of simplifying diabetes management in all of
our markets globally."
This news continues to highlight DarioHealth's agility and
ability to operate around the world. The Australian market is the
second market this month to receive the Dario Lightning®-enabled
device, after our successful launch last week in the U.K.
Germany is the next market
expected to launch the Dario Smart Glucose Meter for iPhone 7,
iPhone 8, and iPhone X. In the U.S. market, the Dario
Lightning®-enabled device is still under review by the U.S. Food
and Drug Administration (F.D.A.), and the Company expects to hear
about possible clearance during the next few months.
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company
serving tens of thousands of users with dynamic mobile health
solutions. We believe people deserve the best tools to manage their
treatment, and harnessing big data, we have developed a unique way
for our users to analyze and personalize their diabetes management.
With our smart diabetes solution, users have direct access to track
and monitor all facets of diabetes, without having the disease slow
them down. The acclaimed Dario™ Blood Glucose Monitoring System
all-in-one blood glucose meter and native smartphone app give users
an unrivaled method for self-diabetes management. DarioHealth is
headquartered in Caesarea, Israel
with an office in New York. For
more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company describes
that it believes it will be able to increase Australian-driven
revenues and achieve greater market penetration, begin
Lightning®-enabled device sales in Germany and in the
United States in the future, and that it expects to hear
from the F.D.A. about possible clearance over the next few months,
it is using forward-looking statements. Readers are cautioned that
certain important factors may affect the Company's actual results
and could cause such results to differ materially from any
forward-looking statements that may be made in this news release.
Factors that may affect the Company's results include, but are not
limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate Contact: Shmuel Herschberg, Marketing Director,
shmuel@mydario.com, +1-914-775-5548
DarioHealth Public Relations Contact: Terese Kelly, Rosica PR, terese@rosica.com,
+1-201-843-5600
DarioHealth Investor Relations Contact: Westwicke
Partners, Dario@Westwicke.com,
+1-443-213-0500
View original
content:http://www.prnewswire.com/news-releases/dariohealth-introduces-iphone-7-iphone-8-and-iphone-x-compatible-smart-glucose-meter-to-the-australian-market-300583818.html
SOURCE DarioHealth Corp.